Pharmacological modulation of septins restores calcium homeostasis and is neuroprotective in models of Alzheimer's disease.


Journal

Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511

Informations de publication

Date de publication:
31 May 2024
Historique:
medline: 30 5 2024
pubmed: 30 5 2024
entrez: 30 5 2024
Statut: ppublish

Résumé

Abnormal calcium signaling is a central pathological component of Alzheimer's disease (AD). Here, we describe the identification of a class of compounds called ReS19-T, which are able to restore calcium homeostasis in cell-based models of tau pathology. Aberrant tau accumulation leads to uncontrolled activation of store-operated calcium channels (SOCCs) by remodeling septin filaments at the cell cortex. Binding of ReS19-T to septins restores filament assembly in the disease state and restrains calcium entry through SOCCs. In amyloid-β and tau-driven mouse models of disease, ReS19-T agents restored synaptic plasticity, normalized brain network activity, and attenuated the development of both amyloid-β and tau pathology. Our findings identify the septin cytoskeleton as a potential therapeutic target for the development of disease-modifying AD treatments.

Identifiants

pubmed: 38815015
doi: 10.1126/science.add6260
doi:

Substances chimiques

Septins EC 3.6.1.-
Calcium SY7Q814VUP
tau Proteins 0
Neuroprotective Agents 0
Amyloid beta-Peptides 0
Calcium Channels 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eadd6260

Auteurs

Katrien Princen (K)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Tom Van Dooren (T)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Marit van Gorsel (M)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Nikolaos Louros (N)

Switch Laboratory, VIB Center for Brain and Disease Research, 3000 Leuven, Belgium.
Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium.

Xiaojuan Yang (X)

Laboratory for Membrane Trafficking, VIB-Center for Brain and Disease Research and Department of Neurosciences, Leuven Brain Institute, 3000 Leuven, Belgium.

Michael Dumbacher (M)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Ilse Bastiaens (I)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Kristel Coupet (K)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Shana Dupont (S)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Eva Cuveliers (E)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Annick Lauwers (A)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Mohamed Laghmouchi (M)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Thomas Vanwelden (T)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Sofie Carmans (S)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Nele Van Damme (N)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Hein Duhamel (H)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Seppe Vansteenkiste (S)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Jovan Prerad (J)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Karolien Pipeleers (K)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Olivier Rodiers (O)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Liese De Ridder (L)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Sofie Claes (S)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Yoni Busschots (Y)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Lentel Pringels (L)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Vanessa Verhelst (V)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Eveline Debroux (E)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Marinka Brouwer (M)

Laboratory of Synapse Biology, VIB Center for Brain & Disease Research and KU Leuven Department of Neurosciences, Leuven Brain Institute, 3000 Leuven, Belgium.

Sam Lievens (S)

Cytokine Receptor Lab, VIB Center for Medical Biotechnology, 9052 Ghent, Belgium.
Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.

Jan Tavernier (J)

Cytokine Receptor Lab, VIB Center for Medical Biotechnology, 9052 Ghent, Belgium.
Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.

Melissa Farinelli (M)

E-PHY-SCIENCE, Bioparc Sophia-Antipolis, 06410 Biot, France.

Sandrine Hughes-Asceri (S)

E-PHY-SCIENCE, Bioparc Sophia-Antipolis, 06410 Biot, France.

Marieke Voets (M)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Joris Winderickx (J)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.
Functional Biology, Department of Biology, KU Leuven, 3001 Leuven-Heverlee, Belgium.

Stefaan Wera (S)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.
ViroVet NV, 3001 Leuven-Heverlee, Belgium.

Joris de Wit (J)

Laboratory of Synapse Biology, VIB Center for Brain & Disease Research and KU Leuven Department of Neurosciences, Leuven Brain Institute, 3000 Leuven, Belgium.

Joost Schymkowitz (J)

Switch Laboratory, VIB Center for Brain and Disease Research, 3000 Leuven, Belgium.
Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium.

Frederic Rousseau (F)

Switch Laboratory, VIB Center for Brain and Disease Research, 3000 Leuven, Belgium.
Switch Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, 3000 Leuven, Belgium.

Henrik Zetterberg (H)

Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, S-431 80 Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, S-431 80 Mölndal, Sweden.
Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.
UK Dementia Research Institute at UCL, London WC1E 6BT, UK.
Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong, China.
Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53792, USA.

Jeffrey L Cummings (JL)

Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas, Las Vegas, NV 89154, USA.

Wim Annaert (W)

Laboratory for Membrane Trafficking, VIB-Center for Brain and Disease Research and Department of Neurosciences, Leuven Brain Institute, 3000 Leuven, Belgium.

Tom Cornelissen (T)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Hans De Winter (H)

Laboratory of Medicinal Chemistry, Department of Pharmaceutical Sciences, University of Antwerp, 2610 Wilrijk, Belgium.

Koen De Witte (K)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Marc Fivaz (M)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Gerard Griffioen (G)

reMYND NV, Bio-Incubator, 3001 Leuven-Heverlee, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH